

Curriculum Vitae

LAURA PASQUALUCCI, M.D.

(date of preparation: February 15, 2012)

Name Laura Pasqualucci
Birth place Perugia, Italy
Citizenship Italian

EDUCATION

1991 M.D., University of Perugia, magna cum laude
1991-1995 Residency in Hematology, University of Perugia, magna cum laude

RESEARCH TRAINING

2/1996-3/1997 Visiting Research Fellow
Molecular Pathology of Lymphoma
Institute of Pathology (Prof. Harald Stein)
Universitätsklinikum B. Franklin, Freie Universität Berlin, Germany

1997-2000 Post-doctoral Research Fellow
Molecular Genetics of Lymphoma (Dr. Riccardo Dalla-Favera)
Institute for Cancer Genetics and the Department of Pathology
Columbia University, New York, NY

2000-2001 Post-doctoral Research Scientist
Molecular Genetics of Lymphoma (Dr. Riccardo Dalla-Favera)
Institute for Cancer Genetics and the Department of Pathology
Columbia University, New York, NY

ACADEMIC APPOINTMENTS

2001-2003 Assistant Professor of Clinical Pathology & Cell Biology
Institute for Cancer Genetics
Columbia University, New York, NY

2003-2006 Professore a contratto
(DM 13.01.2001 n.13: Rientro Cervelli)
Institute of Hematology and Clinical Immunology
University of Perugia Medical School, Perugia, Italy

2007- Associate Professor of Clinical Pathology & Cell Biology
Institute for Cancer Genetics
Herbert Irving Comprehensive Cancer Center
Columbia University, New York, NY

2008-present Associate Professor of Hematology (MED/15)
Institute of Hematology and Clinical Immunology
Department of Clinical and Experimental Immunology
University of Perugia Medical School, Perugia, Italy

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

1993- Italian Society of Experimental Hematology
2010- American Society of Hematology

HONORS

1992 Best thesis in Hematology/Oncology, University of Perugia.
1996 FIRC (Federazione Italiana per la Ricerca sul Cancro) Special Award
1997 AIRC (Associazione Italiana per la Ricerca sul Cancro)
Annual Fellowship in Hematology/Oncology.
1998-2000 American Italian Cancer Foundation Fellowship
2002-2005 The Leukemia & Lymphoma Society, Special Fellow Grant
2006-2008 Julie Gould Scholar
2009- BLOOD-Editorial Board
2009- Lymphoma Research Foundation-Panel of Scientific Advisors
2012- NIH Peer Review Committee-SPORE in Lymphoma, ad hoc reviewer

SELECTED INVITED LECTURES and SEMINARS

June 2000 Ninth Meeting of the New York Human Genetics Club
The Rockefeller University, NY (Organized by L. Luzzatto)
June 2000 Fifth Congress of the European Haematology Association
Birmingham, UK
October 2001 The Leukemia Society Stohlman Symposium
Charlotte, NC
October 2001 The Fox Chase Cancer Center Annual Symposium
Fox Chase Cancer Center, Philadelphia, PA
March 2003 USCAP 92nd Annual Meeting. Society for Hematopathology
Washington, DC
April 2003 First International Symposium on Childhood and Adolescent Non-
Hodgkin's Lymphoma: State of the Art and Future Needs in
Cytogenetic/Molecular Genetics/Arrays workshop.
New York, NY
July 2003 FASEB Summer Research Conference on Hematologic Malignancies
Saxtons River, VT
February 2005 The Banbury Center, Cold Spring Harbor Laboratory: Meeting on Chronic
Lymphocytic Leukemia (Organized by N. Chiorazzi, KR Rai, M Wigler)
March 2005 Pathology Research Seminar Series
Cornell University, New York, NY
August 2005 Think Tank on Molecular Targets in Lymphoid Malignancies
National Institutes of Health, Bethesda, Maryland

September 2006 The 12th Danish Cancer Society Symposium
Copenhagen, Denmark

September 2006 Third International Conference on: Innovative Therapies for
Lymphoid Malignancies
Palermo, Italy

October 2006 Haematology Society of Australia & New Zealand Meeting
Hobart, Tasmania (Australia)

January 2007 MD Anderson Cancer Center, Houston USA
Hematology Oncology Seminar Series

September 2007 Novel Therapeutic Developments in Lymphoma Workshop
American Society of Clinical Oncology
Aspen, CO

October 2007 American Society of Hematology State of the Art Symposium
Philadelphia, PA

January 2008 The Belgian Hematological Society 23rd Annual Meeting.
Keynote lecture
Oostende, Belgium

September 2008 Workshop on AID biology and disease
University of North Carolina
Chapel Hill, NC

September 2008 National Cancer Institute Hematopoietic Malignancies 4: Modeling,
Biology and Therapy Workshop
Harvard Medical School
Boston, MA

February 2009 TRR 54-Meeting Lymphoma Conference
Charité Universitaetsmedizin Berlin
Berlin, Germany

April 2009 International Extranodal Lymphoma Study Group Annual Meeting
Toronto, Canada

August 2009 FASEB Summer Research Conference
Hematologic Malignancies
Saxtons River, VT

November 2009 Association for Molecular Pathology Annual Meeting
Kissimmee, FL

January 2010 Keystone Symposia on NF- κ B in Inflammation and Disease
Santa Fe, NM

March 2010 Primo Congresso di Oncoematologia Molecolare
Risvolti Clinici e Terapeutici
Torino, Italy

April 2010 JINML Forum 2010
Tokyo, Japan

April 2010 AACR 101st Annual Meeting
New Concepts in Organ Site Research
Washington, DC

May 2010 Fourth International Conference on Innovative Therapies for Lymphoid
Malignancies
Palermo, Italy

June 2010 European Haematology Association
Barcelona, Spain

September 2010 San Raffaele Hospital Systems Biology Workshop
Milan, Italy

- October 2010 National Cancer Institute Hematopoietic Malignancies 5: Modeling, Biology and Therapy Workshop
Harvard Medical School
Boston, MA
- October 2010 Normal and Malignant Hematopoiesis Research Affinity Group Seminar Series
The Children's Hospital of Philadelphia
Philadelphia, PA
- November 2010 Memorial Sloan Kettering Cancer Center Grand Rounds
Oncogenomics of B cell non-Hodgkin's lymphoma
New York, NY
- February 2011 7th Annual Hematological Malignancies Symposium
Hollings Cancer Center of the Medical University of South Carolina
Charleston, SC
- June 2011 16th Congress of the European Haematology Association
London, England
- October 2011 Cancer Research UK Centre
University of Liverpool
Liverpool, United Kingdom
- October 2011 UK Lymphoma Trials Meeting
Mike Bennet Guest Lecture
London, United Kingdom
- November 2011 National Cancer Institute, NIH
Clinical Cancer Research Grand Rounds Lecture Series
Bethesda, MD
- December 2011 The 2nd Symposium for the Tenure Track Program
Tokai University Institute of Innovative Science and Technology
Tokyo, Japan

TEACHING EXPERIENCE AND RESPONSIBILITIES

- 1997 Corso Integrativo dell' Insegnamento Ufficiale di Malattie del Sangue e degli Organi Emopoietici, Scuola di Specializzazione in Ematologia, University of Perugia Medical School, Perugia, Italy
- 2003-2006 Biologia molecolare dei Linfomi non-Hodgkin: Aspetti Patogenetici e Diagnostici. Corso Integrativo dell'Insegnamento Ufficiale di Malattie del Sangue e degli Organi Emopoietici, rivolto agli studenti di Medicina e Chirurgia ed agli iscritti alla Scuola di Specializzazione in Ematologia.
University of Perugia Medical School, Perugia, Italy
- 2006- Course in Cancer Genetics, Columbia University, New York, NY
Lymphoma as a Cancer Model.
- 2008- Fellowship Scholarly Oversight Committee, Columbia University, New York, NY
Divisions of Pediatric Hematology, Blood and Marrow Transplantation
- 2010 Hematology/Oncology Grand Rounds Seminar Series
Columbia University, New York, NY
- 2010 Lymphoid Development and Malignancies Program
Herbert Irving Comprehensive Cancer Center
Columbia University, New York, NY
- 2010 Patogenesi Molecolare dei Linfomi non-Hodgkin.
University of Perugia Medical School, Perugia, Italy

2011- Corso di Laurea Magistrale in Scienze Biotecnologiche Mediche, Veterinarie e Forensi
Modulo di Malattie del Sangue
University of Perugia Medical School, Perugia, Italy

OTHER PROFESSIONAL ACTIVITIES

Editorial Review

- BLOOD- Editorial Board Member; Reviewer
- NATURE-Reviewer
- NATURE GENETICS-Reviewer
- NEW ENGLAND JOURNAL OF MEDICINE-Reviewer
- CANCER CELL-Reviewer
- JOURNAL OF EXPERIMENTAL MEDICINE-Reviewer
- JOURNAL OF CLINICAL INVESTIGATION-Reviewer
- CLINICAL CANCER RESEARCH- Reviewer
- CANCER RESEARCH-Reviewer
- LEUKEMIA-Reviewer
- HAEMATOLOGICA- Reviewer
- LEUKEMIA RESEARCH- Reviewer
- JOURNAL OF PATHOLOGY-Reviewer
- EXPERIMENTAL HEMATOLOGY- Reviewer
- HEMATOLOGICAL ONCOLOGY- Reviewer
- ACTA HEMATOLOGICA- Reviewer
- ACTA NEUROPATHOLOGICA- Reviewer
- AMERICAN SOCIETY OF HEMATOLOGY-reviewer of abstracts for the annual national meeting
- EUROPEAN SOCIETY OF HEMATOLOGY- reviewer of abstracts for the annual national meeting
- INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA - LUGANO - reviewer of abstracts

Consultative Activities

- LYMPHOMA RESEARCH FOUNDATION- Panel of Scientific Advisors
- INSTITUT NATIONAL DU CANCER, PARIS, FRANCE. Programme d'Action Intégrées de Recherche sur les lymphomes (NATIONAL AGENCY FOR CANCER, Lymphoma Program) – Scientific Evaluation Committee
- AUSTRIAN SCIENCE FUND (FWF) - Reviewer for the Erwin Schrodinger Program Fellowship applications
- ITALIAN MINISTRY OF HEALTH-Bando MoH2010 - Grants Reviewer
- NIH/NCI PEER REVIEW COMMITTEE-SPORE program - Grants Reviewer
- CANCER RESEARCH UK-Training & Career Development Board - Career Development Fellowships Reviewer
- NATIONAL PRIORITIES RESEARCH PROGRAM (NPRP) - Qatar National Research Fund - Peer Reviewer

PUBLICATIONS

(date of preparation: February 15, 2012)

Original, peer reviewed articles:

1. Comparison of immunosuppressive effects of single-dose and hyperfractionated total body irradiation. *Transplant Proc*, 1994; 26: 3217.
2. Falini B, Venturi S, Martelli MF, Santucci A, Pileri S, Pescarmona E, Giovannini M, Mazza P, Martelli MF, **Pasqualucci L**, Ballatori E, Guglielmi C, Amadori S, Poggi S, Sabattini E, Gherlinzoni F, Zinzani PL, Baroni CD, Mandelli F, Tura S. Mediastinal large B-cell lymphoma: clinical and immunohistologic findings in 18 patients treated with different third- generation regimens. *Br J Haematol*, 1995; 89: 780-789.
3. **Pasqualucci L**, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/Saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. *Blood*, 1995; 85: 2139-2146.
4. Terenzi A, Bolognesi A, **Pasqualucci L**, Flenghi L, Pileri S, Stein H, Kadin ME, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B. Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. *Br J Haematol*, 1996; 92(4): 872-879.
5. Flenghi L, Bigerna B, Fizzotti M, Venturi S, **Pasqualucci L**, Pileri S, Ye BH, Gambacorta M, Pacini R, Baroni CD, Pescarmona E, Anagnostopoulos I, Stein H, Asdrubali G, Martelli MF, Pelicci PG, Dalla-Favera R, Falini B. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. *Am J Pathol*, 1996; 148(5): 1543-1555.
6. Falini B, Bigerna B, **Pasqualucci L**, Fizzotti M, Martelli MF, Pileri S, Pinto A, Carbone A, Venturi S, Pacini R, Cattoretti G, Pescarmona E, Lo Coco F, Pelicci PG, Anagnostopoulos I, Dalla-Favera R, Flenghi L. Distinctive expression pattern of the Bcl-6 protein in nodular lymphocyte predominance Hodgkin's disease. *Blood*, 1996; 87: 465-471.
7. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, Pacini R, Tanci LN, **Pasqualucci L**, Ascani S, Mencarelli A, Liso A, Pelicci PG, Falini B. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. *Am J Pathol*, 1996; 149: 2023-1035.
8. Falini B, Liso A, **Pasqualucci L**, Flenghi L, Ascani S, Pileri S, Bucciarelli E. CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance. *Histopathology*, 1997; 30: 90-92.

9. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, **Pasqualucci L**, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). *Blood*, 1997; 90: 4046-4053.
10. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Lemoli R, Terenzi A, **Pasqualucci L**, Falini B, Stirpe F. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. *Br J Haematol*, 1998; 101(1): 179-188.
11. Qu X-Y, Hauptschein RS, Rzhetsky, Scotto L, Chien M-C, Ye X, Frigeri F, Rao PH, **Pasqualucci L**, Gamberi B, Deaven LL, Zhang P, Chaganti RSK, Dalla-Favera R, Russo JJ. Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. *DNA Sequence*, 1998; 9 (4): 189-204.
12. **Pasqualucci L**, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RSK, Klein U, Kuppers R, Rajewsky K, Dalla-Favera R. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci USA*, 1998; 95 (20): 11816-11821.
13. Capello D, Vitolo U, **Pasqualucci L**, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G, Dalla-Favera R, Carbone A, Gaidano G. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. *Blood*, 2000; 95(2): 651-659.
14. **Pasqualucci L**, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. *Cancer Res*, 2000; 60 (20): 5644-5648.
15. **Pasqualucci L**, Neumeister P, Goossens T, Nanjangud G, Chaganti RSK, Küppers R, Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell Diffuse Large Cell Lymphomas *Nature*, 2001; 412: 341-346.
16. **Pasqualucci L**, Migliazza A, Ye HB, Dalla-Favera R. Transcriptional Deregulation of Mutated BCL6 Alleles by Loss of Negative Autoregulation in Diffuse Large B Cell Lymphoma. *Am. N.Y. Acad. Sci*, 2003; 987(49):314-316.
17. **Pasqualucci L**, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood*, 2003; 101(8): 2914-2923.
18. Gaidano G, **Pasqualucci L**, Capello D, Berra E, Deambrogi C, Rossi D, Larocca LM, Gloghini A, Carbone A, Dalla-Favera R. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood*, 2003; 102(5): 1833-1841.
19. Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, Droetto S, Galletti BV, Gambacorta M, Orazi A, **Pasqualucci L**, Miller I, Küppers R, Dalla-Favera R, Cattoretti G.

Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). *Blood*, 2003; 102(10): 3684-3692.

20. **Pasqualucci L***, Guglielmino R, Houldsworth J, Mohr J, Reynaud CA, Polakiewicz R, Chaganti RSK, Dalla-Favera R. Expression of the AID protein in normal and neoplastic B cells. *Blood*, 2004; 104(10):3318-3325. (*corresponding author)
21. Cerri M, Capello D, Muti G, Rambaldi A, Paulli M, Gloghini A, Berra E, Deambrogi C, Rossi D, Franceschetti S, Conconi A, Morra E, **Pasqualucci L**, Carbone A, Gaidano G. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. *Br J Haematol*, 2004; 127(3):362-364.
22. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, **Pasqualucci L**, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood*, 2005; 105(5):1851-1861.
23. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, **Pasqualucci L**, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med*, 2005; 352(3): 254-66.
24. Libra M, Capello D, Gloghini A, **Pasqualucci L**, Berra E, Cerri M, Gasparotto D, Franca S, De Re V, Gaidano G, Carbone A. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. *J Pathol*, 2005; 206(1):87-91.
25. Cattoretti G[^], **Pasqualucci L[^]**, Ballon G, Tam W, Nandula SN, Shen Q, Mo T, Murty VV, Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B-cell lymphomas in mice. *Cancer Cell*, 2005; 7:445-455. ([^]equal contribution)
26. Winkler D, Schneider C, Krober A, **Pasqualucci L**, Lichter P, Dohner H, Stilgenbauer S. Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL). *Leukemia*, 2005; 19: 1211-1215.
27. Rossi D, Cerri M, Capello D, Deambrogi C, Berra E, Franceschetti S, Alabisio O, Gloghini A, Paulli M, Carbone A, Pileri SA, **Pasqualucci L**, Gaidano G. Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. *Leukemia*, 2005; 19: 2363-2366.
28. **Pasqualucci L***, Kitaura Y, Gu H, Dalla-Favera R. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. *Proc Natl Acad Sci USA*, 2006; 103: 395-400. (*corresponding author)
29. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, **Pasqualucci L**, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood*, 2006; 107: 4514-4523.

30. **Pasqualucci L**, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, and Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 Gene in Diffuse Large B-cell Lymphoma. *J Exp Med*, 2006; 203: 311-317.
31. Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V, Paulli M, Carbone A, Del Sol G, Campo E, Pileri S, **Pasqualucci L**, Gaidano G and Falini B. Aberrant somatic hypermutation in nodular lymphocyte-predominant and classical Hodgkin's lymphoma. *Blood*, 2006; 108: 1013-1020.
32. **Pasqualucci L**, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A, Carini M, Bigerna B, Pucciarini A, Mannucci R, Nicoletti I, Tiacci E, Meloni G, Specchia G, Cantore G, Di Raimondo F, Pileri A, Mecucci C, Mandelli F, Martelli MF, and Falini B. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. *Blood*, 2006; 108: 4146-4155.
33. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, Lunghi M, Conconi A, Paulli M, Matolesy A, **Pasqualucci L**, Capello D, Gaidano G. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. *Haematologica*, 2006; 91:1405-1409.
34. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, **Pasqualucci L**, Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. *Cancer Cell*, 2007; 12: 280-292.
35. **Pasqualucci L***, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC 3rd, Nussenzweig MC, Dalla-Favera R*. AID is required for germinal center-derived lymphomagenesis. *Nature Genetics*, 2008; 40:108-112. (*co-corresponding authors).
36. **Pasqualucci L**, Li S, Meloni G, Schnittger S, Gattenlohner S, Liso A, Di Ianni M, Martelli MP, Pescarmona E, Foa R, Haferlach T, Skoda RC, Falini B. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? *Leukemia*, 2008; 22(7):1459-1463.
37. Vakiani E, Basso K, Klein U, Mansukhani NM, Narayan G, Smith PM, Murty VV, Dalla-Favera R, **Pasqualucci L**, Bhagat G. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. *Hematol Oncol*, 2008; 26(4): 199-211.
38. Novak U, Rinadi A, Kwee I, Nandula SV, Rancoita PMV, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, **Pasqualucci L**, Bhagat G, Bertoni F. The NF- κ B negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. *Blood*, 2009; 13(20):4918-4921.
39. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, **Pasqualucci L**. Mutations in

multiple genes cause deregulation of the NF- κ B pathway in diffuse large B-cell lymphoma. *Nature*, 2009; 459(7247):717-721.

40. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Bhagat G, Califano A, Chadburn A, **Pasqualucci L**, Dalla-Favera R. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc Natl Acad Sci USA*, 2009; 106(27):11294-11299.
41. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, Dalla-Favera R, **Pasqualucci L***, MacLennan AJ*. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. *Cancer Research*, 2009; 69(22):8686-8692. (*co-corresponding authors).
42. Mandelbaum J, Bhagat G, Tang H, Mo T, Grunn A, Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovskiy A, **Pasqualucci L***, Dalla-Favera R*. Blimp1 is a tumor suppressor gene frequently disrupted in activated B-cell like diffuse large B cell lymphoma. *Cancer Cell*, 2010; 18(6):568-579. (*co-corresponding authors).
43. Green MR, Monti S, Dalla-Favera R, **Pasqualucci L**, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. *Proc Natl Acad Sci USA*, 2011; 108(7):2873-8.
44. **Pasqualucci L***, Dominguez-Sola D, Chiarenza A, Fabbri A, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK and Dalla-Favera R*. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature*, 2011; 471(7337):189-95. (*co-corresponding authors).
45. Tiacci E, Trifonov V, Schiavoni G, Holmes AB, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells V, Sportoletti P, Pettirossi V, Mannucci R, Elliot O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foa' R, Farinelli L, Haferlach T, **Pasqualucci L**, Rabadan R, Falini B. *BRAF* mutations in Hairy Cell Leukemia, *N Engl J Med*, 2011; 364(24):2305-2315.
46. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabani H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscieri D, Bertoni F, Mullighan CG, Foa' R, **Pasqualucci L***, Rabadan R*, Dalla-Favera R*, Gaidano G*. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med*, 2011; 208(7):1389-1401. (*equal contribution)
47. **Pasqualucci L***, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R*. Analysis of the coding genome of diffuse large B cell lymphoma. *Nature Genetics*, 2011; 43:830-837, 2011. (*co-corresponding authors)
48. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Brusca A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foa' R, Bertoni F, Dalla-Favera R, **Pasqualucci L**, Gaidano G. Alterations of *BIRC3* and multiple other NF- κ B pathway genes in splenic marginal

zone lymphoma. *Blood*, 2011; 118(18):4930-4934.

49. Novak U, Basso K, **Pasqualucci L**, Dalla-Favera R, Bhagat G. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. *Br J Haematol*, 2011; 155(3):362-365.
50. Tiacci E, Spanhol-Rosseto A, Martelli MP, **Pasqualucci L**, Quentmeier H, Grossmann V, Drexler HG, Falini B. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. *Leukemia*, 2011 Sep 9 [Epub ahead of print].
51. Grossmann V, Tiacci E, Holmes A, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan^R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, **Pasqualucci L**, Rabadan R, Haferlach T, Falini B. Whole-exome sequencing identifies mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood*, 2011; 118(23): 6153-6163.
52. Rossi D, Bruscazzin A, Spina V, Rasi S, Khiabani H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, **Pasqualucci L**, Foà R, Dalla-Favera R, Gaidano G. Blood. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood*, 2011; 118(26): 6904-6908.]
53. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscazzin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, **Pasqualucci L**, Dalla-Favera R, Foà R, Gaidano G. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood*, 2011; 119(2): 521-529.
54. Challa-Malladi M, Lieu YK, Califano O, Holmes A, Bhagat G, Murty VV, Dominguez-Sola D, **Pasqualucci L***, Dalla-Favera R*. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell*, 2011; 20(6): 728-740. (*equal contribution)
55. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscazzin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, **Pasqualucci L**, Guarini A, Dalla-Favera R, Foà R, Gaidano G. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia. *Blood*, 2012 Feb 3 [Epub ahead of print].

Reviews, chapters and editorials:

• **Review Articles**

1. Falini B, Flenghi L, **Pasqualucci L**, Martelli MF, Venturi S, Scarpelli N, Blass A, Stirpe F, Pileri S, Martelli MF. Gli anticorpi monoclonali nella terapia delle emopatie maligne. *Hematologica*, 1993.

2. **Pasqualucci L**, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Falini B: Immunotoxin therapy of hematopoietic malignancies. *Hematologica* 1995; 80: 551-559.
3. Falini B, Fizzotti M, Pileri S, Liso A, **Pasqualucci L**, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. *Ann Oncol* 1997; 8, Suppl 2: 101-104.
4. Gaidano G, Capello D, Gloghini A, Pastore C, Migliazza A, Quattrone S, Savinelli F, Buonaiuto D, Cilia AM, Perin T, **Pasqualucci L**, Canzonieri V, Saglio G, Dalla-Favera R, Carbone A. BCL-6 in AIDS-related lymphomas: pathogenetic and histogenetic implications. *Leukemia and Lymphoma* 1998; 31(1-2): 39-46.
5. Dalla-Favera R, Migliazza A, Chang CC, Niu H, **Pasqualucci L**, Butler M, Shen Q, Cattoretti G. Molecular pathogenesis of B cell malignancy: the role of BCL-6. *Curr Top Microbiol Immunol* 1999; 246:257-263.
6. Harris NL, Stein H, Coupland SE, Hummel M, Dalla-Favera R, **Pasqualucci L**, Chan WC. New approaches to lymphoma diagnosis. *Hematology* (Am Soc Hematol Educ Program) 2001; 194-220.
7. **Pasqualucci L**, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, Cattoretti G, and Dalla-Favera R. Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the role of BCL6. *Leukemia & Lymphoma* 2003, 69:927-931.
8. Heerema NA, Bernheim A, Lim MS, Look AT, **Pasqualucci L**, Raetz E, Sanger WG, Cairo MS. State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: Summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. *Pediatr Blood Cancer* 2005; 45(5):616-22.
9. Klein U, **Pasqualucci L**. B cell receptor signaling derailed in lymphomas. *Immunol Cell Biol* 2010; 88(4):346-347.
10. Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, Lowe SW, Guo X, Krasnitz A, Sawey ET, Sordella R, Stein L, Trotman LC, Califano A, Dalla-Favera R, Ferrando A, Iavarone A, **Pasqualucci L**, Silva J, Stockwell BR, Hahn WC, Chin L, DePinho RA, Boehm JS, Gopal S, Huang A, Root DE, Weir BA, Gerhard DS, Zenklusen JC, Roth MG, White MA, Minna JD, MacMillan JB, Posner BA. Towards patient-based cancer therapeutics. *Nat Biotechnol* 2010; 28: 904-906.
11. **Pasqualucci L**. Relevant Pathogenetic Pathways in Diffuse Large B cell Lymphoma. *16th Congress of the European Hematology Association, Education Session on Diffuse Large B cell Lymphoma* 2011.
12. Schneider C, **Pasqualucci L**, Dalla-Favera R. Molecular Pathogenesis of diffuse large B-cell lymphoma. *Semin Diagn Pathol* 2011; 28(2):167-177.

- **Textbook chapters**

1. Flenghi L, **Pasqualucci L**, Bigerna B, Pacini R, Natali-Tanci L, Venturi S, Pileri S, Falini B. Linfoma/Leucemia dei precursori linfoidi. In: *Linfomi non-Hodgkin*, attualita' di diagnosi e terapia, Seminari di Ematologia, Vol 1, 1995.
2. Falini B, Terenzi A, Liso A, Flenghi L, Solinas A, **Pasqualucci L**. Targeted Antibodies in the Treatment of Lymphomas. J Tooze and A.C. Wotherspoon (eds.). In: *Cancer Surveys*, Vol 30: *Lymphoma*. Cold Spring harbor Laboratory Press (publ.) 1997: 295-309.
3. Dalla-Favera R and **Pasqualucci L**. Molecular Genetics of Lymphoma. PM Mauch, JO Armitage, B Coiffier, R Dalla-Favera, NL Harris (eds.). In: *Non-Hodgkin's Lymphomas*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2009: 115-129.
4. Novak U, **Pasqualucci L** and Dalla-Favera R. Molecular Biology of Lymphoma. VT. DeVita, Jr., TS Lawrence, and SA Rosenberg (eds). In: *DeVita, Hellman, and Rosenberg's. Cancer: Principles and Practices of Oncology*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2011.

• **FELLOWSHIPS AND GRANT SUPPORT**

COMPLETED

Fellowship Award (Pasqualucci) 6/1/00/6/1/02
American-Italian Cancer Foundation Fellowship
Role of BCL6 mutations in Lymphomagenesis
Investigating the distribution and functional consequences of mutations affecting the BCL6 gene in Diffuse Large B cell Lymphoma
Role: Fellow

Special Fellow Award (Pasqualucci) 7/1/02-6/30/05
Leukemia and Lymphoma Society
Aberrant Hypermutation in Diffuse Large B-Cell Lymphoma
Understanding the role of aberrant somatic hypermutation in the development of lymphoma and possibly identifying new targets for diagnosis and therapy
Role: Fellow

5 R37 CA37295-23 (Dalla-Favera) 7/1/02-6/30/07
NIH/NCI
Aids-Associated Lymphoproliferative Disorders
Major goals. (1) Analyzing the phenotype of AIDS-NHL subtypes by gene expression profiling; (2) determine the pathogenetic role in AIDS-NHL aberrant somatic hypermutation
This grant has been designated a MERIT AWARD.
Role on project: co-investigator

5 P01 CA92625-05 (PI: Shipp) 8/2/01-6/30/06
NIH/NCI through Dana Farber
Molecular Targets of Germinal Center B-cell Lymphomas
Project 3: *Role of BCL-6 in Germinal Center formation and Lymphomagenesis.*
Role: Project 3 Co-investigator
(competing renewal will be funded)

Specialized Center of Research 7032-04 (PI: Dalla-Favera) 10/1/03 – 9/30/08
Leukemia and Lymphoma Society.
Molecular Targets in Lymphoma
The goal of this program is to understand the pathogenesis of B cell-derived non-Hodgkin lymphoma and improve the diagnosis and treatment of the disease.
Project 1 (Dalla-Favera)
Aberrant Somatic Hypermutation in Diffuse Large Cell Lymphoma
Role on project: co-investigator

5 R01 CA107489-03 (Dalla-Favera) 5/5/04 – 4/30/09
NIH/NCI
Role of BCL6 Mutations in Lymphomagenesis
Major goals. (1) to investigate the role of BCL6 mutations on the regulation of BCL6 expression; (2) to test whether BCL6 mutations contribute to lymphomagenesis; (3) to examine the role of germinal centers and IgV somatic hypermutation in lymphomagenesis.

Role on project: co-investigator

Stewart Trust Pilot Project (Pasqualucci)

7/1/09 – 6/30/10

Role of BLIMP1 inactivation in diffuse large B cell lymphoma

Major

goals. (1) Investigate epigenetic mechanisms of BLIMP1 inactivation in ABC-DLBCL; 2) Examine the role of BLIMP1 inactivation in lymphomagenesis in vivo, by using mouse models that recapitulate the genetic lesion observed in the human disease.

5 R01 CA107489-05 (Dalla-Favera)

5/5/04 – 4/30/10

NIH/NCI

Role of BCL6 Mutations in Lymphomagenesis

Major goals. (1) to investigate the role of BCL6 mutations on the regulation of BCL6 expression; (2) to test whether BCL6 mutations contribute to lymphomagenesis; (3) to examine the role of germinal centers and IgV somatic hypermutation in lymphomagenesis.

Role on project: co-investigator

ACTIVE

5 P01 CA92625-07 (PI: Shipp)

7/1/06 – 6/30/11

NIH-Dana-Farber Cancer Institute Subcontract to Columbia

Molecular Targets of Germinal Center B-cell Lymphomas

Project 3 (Dalla-Favera)

Role of BCL-6 in germinal Center formation and Lymphomagenesis

Role on project: co-investigator
(competing renewal will be funded)

4 R37 CA37295-24 (Dalla-Favera)

7/1/07 – 6/30/12

NIH/NCI

AIDS-Associated Lymphoproliferative Disorders

Major goals. (1) Analyzing the phenotype of AIDS-NHL subtypes by gene expression profiling; (2) determine the pathogenetic role in AIDS-NHL aberrant somatic hypermutation *Merit award continuation*

Role on project: co-investigator

Specialized Center of Research (PI: Dalla-Favera)

10/1/08 – 9/30/13

Leukemia and Lymphoma Society.

Molecular Targets in Lymphoma

Project 1 (Dalla-Favera)

Aberrant Somatic Hypermutation in Diffuse Large Cell Lymphoma

Role on project: co-investigator

Core C (Pasqualucci)

Genomics Core

Role on project: Core leader

Work Address

Istituto di Ematologia e Immunologia Clinica
Dipartimento di Medicina Clinica e Sperimentale
Ospedale S. Maria della Misericordia
Loc S. Andrea delle Fratte
06132 PERUGIA (PG)